Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Nurix Therapeutics Inc shares valued at $59,598 were sold by van Houte Hans on Aug 01 ’25. At $11.03 per share, van Houte Hans sold 5,402 shares. The insider’s holdings dropped to 35,512 shares worth approximately $0.33 million following the completion of this transaction.
Also, JOHANNES VAN HOUTE purchased 5,402 shares, netting a total of over 60,827 in proceeds.
Before that, van Houte Hans had sold 4,304 shares from its account. In a trade valued at $51,695, the Chief Financial Officer traded Nurix Therapeutics Inc shares for $12.01 each. Upon closing the transaction, the insider’s holdings decreased to 4,304 shares, worth approximately $0.39 million.
As published in their initiating research note from Leerink Partners on March 17, 2025, Nurix Therapeutics Inc [NRIX] has been a Market perform and the price target has been revised to $16. Analysts at BTIG Research started covering the stock with ‘”a Buy”‘ outlook in a report released in early December. As of December 06, 2024, BMO Capital Markets has initiated its “an Outperform” rating for NRIX. Earlier on October 24, 2024, UBS initiated its rating. Their recommendation was “a Buy” for NRIX stock.
Analyzing NRIX Stock Performance
On last trading session, Nurix Therapeutics Inc [NASDAQ: NRIX] plunged -1.47% to $9.41. The stock’s lowest price that day was $9.31, but it reached a high of $9.71 in the same session. During the last five days, there has been a drop of approximately -2.49%. Over the course of the year, Nurix Therapeutics Inc shares have dropped approximately -63.37%. Shares of the company reached a 52-week high of $20.66 on 01/27/25 and a 52-week low of $8.18 on 04/10/25.
Support And Resistance Levels for Nurix Therapeutics Inc (NRIX)
According to the 24-hour chart, there is a support level at 9.24, which, if violated, would cause prices to drop to 9.08. In the upper region, resistance lies at 9.64. The next price resistance is at 9.88. RSI (Relative Strength Index) is 35.98 on the 14-day chart, showing neutral technical sentiment.
Is Nurix Therapeutics Inc subject to short interest?
Stocks of Nurix Therapeutics Inc saw a sharp steep in short interest on 2025-08-15 dropping by -1.07 million shares to 12.88 million. Data from Yahoo Finance shows that the short interest on 2025-07-15 was 13.95 million shares. A decline of -8.31% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 18.2 of the overall float, the days-to-cover ratio (short ratio) decline to 18.2.
Which companies own the most shares of Nurix Therapeutics Inc (NRIX)?
In terms of Nurix Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 16 in the next 12 months, up nearly 67.54% from the previous closing price of $9.55. Analysts anticipate Nurix Therapeutics Inc stock to reach 30 by 2025, with the lowest price target being 16. In spite of this, 16 analysts ranked Nurix Therapeutics Inc stock as Buy at the end of 2025. On October 11, 2024, Jefferies assigned a price target of “a Buy” to the stock and initiated coverage with a $41.
